Physician profile
Megan Eileen Morrison
NPI 1306159728
$9,838.35
in general payments reported to CMS, 2019-2025
35 companies · $1,689 in 2025
The $1,689 reported for 2025 was more than what 86% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $545 · 2021: $1,186 · 2022: $1,717 · 2023: $1,686 · 2024: $2,303 · 2025: $1,689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,478 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,478.26 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,882.78 | 2019-2025 | |
| Lilly USA, LLC | $1,011.92 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $915.88 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $807.67 | 2020-2025 | Tremfya |
| Genzyme Corporation | $746.23 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $546.46 | 2019-2025 | |
| Ucb, INC. | $466.31 | 2020-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $466.13 | 2020-2025 | Ilumya, Blu-U, Odomzo |
| Genentech USA, INC. | $414.31 | 2019-2024 | Erivedge |
| Leo Pharma INC. | $373.93 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $337.75 | 2019-2025 | |
| Incyte Corporation | $312.79 | 2022-2025 | Opzelura |
| Amgen INC. | $302.34 | 2019-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $240.27 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.35 | 2022-2025 | Spevigo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $158.52 | 2024-2025 | Daxxify |
| Biofrontera INC. | $71.24 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $69.65 | 2022-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $65.86 | 2023-2024 | Ycanth |
| Mayne Pharma Commercial LLC | $63.54 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $52.60 | 2025 | Acthar |
| Convatec INC. | $50.49 | 2025 | |
| Dusa Pharmaceuticals, INC. | $44.71 | 2019 | |
| Organon LLC | $30.89 | 2025 | Vtama |
| Dermira, INC. | $30.77 | 2020-2021 | |
| Promius Pharma LLC | $29.25 | 2019 | |
| Almirall LLC | $29.03 | 2023 | Klisyri |
| Merck Sharp & Dohme LLC | $24.97 | 2019 | |
| Celgene Corporation | $24.65 | 2019 | |
| Fresenius Kabi USA, LLC | $23.95 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2023 | Sotyktu |
| Genentech, INC. | $15.35 | 2023 | Erivedge |
| Paratek Pharmaceuticals, INC. | $14.32 | 2025 | Nuzyra |
| Nabriva Therapeutics, Plc | $11.87 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.